Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tilray Brands Inc TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Post by Ventura2020on Aug 30, 2023 7:09pm
164 Views
Post# 35612913

Cannabis ReClassified

Cannabis ReClassified

Like I have been saying for weeks now. The FDA started this ball rolling. 

 

And this just may, just may all go to Congress through the Farm Bill.
Read the highlights carefully.

I believe the FDA will have control of this industry...If this gets passed.

Cheers,
V

According to an August 29, 2023 letter, the Department of Health and Human Services (“HHS”) has recommended to the Drug Enforcement Agency (“DEA”) that cannabis be reclassified as a schedule III drug under the Controlled Substances Act (“CSA”). HHS based this recommendation on a Food and Drug Administration (“FDA”) review  of cannabis’s classification pursuant to President Biden’s executive order in October 2022.

 

Rescheduled to schedule III would be monumental for state-legal cannabis businesses.  Although rescheduling would not federally legalize the state-legal programs, it would eliminate the 280E tax burden that currently applies to such businesses.

 

To arrive at a schedule III finding, HHS, via the FDA, had to conduct a scientific and medical evaluation of cannabis, using a statutorily required eight-factor analysis. The DEA also conducts its own independent review of cannabis using this eight-factor analysis, but, unlike the FDA, it may also consider “all other relevant data”—an unrestricted term that, by definition, permits the DEA to look broadly outside the statutory limits placed upon the FDA.

Now the DEA will review the FDA’s recommendations, its own findings, and the relevant facts to determine on its own the proper scheduling of cannabis.       






 

<< Previous
Bullboard Posts
Next >>